Cochrane Review Finds New Alzheimer's Drugs Offer Insignificant Clinical Benefits

A landmark review by the Cochrane Collaboration, published on April 16, 2026, concluded that the clinical benefits of anti-amyloid Alzheimer's drugs such as lecanemab and donanemab are "non-existent or insignificant," dealing a significant blow to one of the most heavily funded research directions in modern neurology. The review analyzed data from 17 randomized clinical trials involving , comparing five different monoclonal antibodies against placebo treatments over 18 months. Lead author Francesco Nonino, a neurologist and epidemiologist at the IRCCS Istituto delle Scienze Neurologiche di Bologna, stated that while the drugs successfully removed amyloid plaques from the brain, this biological change did not translate into perceptible improvements in patients' lives. The review found that effects on cognitive function and dementia severity fell below the minimum thresholds considered clinically relevant. The findings arrive as health authorities in Spain and Germany have independently moved to restrict or deny public funding for these treatments.

Spain halts public funding, Germany denies added benefit Spain's Ministry of Health, acting through the Interministerial Commission on Drug Prices, announced a halt to public financing of lecanemab, sold under the brand name Leqembi, citing cost rationalization criteria and a lack of effective cost-benefit justification. The cost of the drug can reach approximately , a figure that has driven intense debate among patient associations and medical professionals who had awaited its inclusion in the public system. In Germany, the Federal Joint Committee certified that lecanemab has "no added benefit" compared to standard therapy, following an identical ruling on donanemab issued in January 2026. Leqembi had been approved in Germany in September 2025, with donanemab receiving approval two months later in November 2025. Despite the G-BA rulings, both drugs may still be prescribed in Germany, with the assessments now serving as the basis for price negotiations between the National Association of Statutory Health Insurance Funds and manufacturers. France and the United Kingdom had previously decided not to reimburse the costs of these treatments through their respective health insurance systems.

Anti-amyloid drugs: key regulatory milestones: — ; — ; — ; —

Brain swelling and microhemorrhages identified as notable risks Beyond the question of efficacy, the Cochrane review identified significant safety concerns associated with anti-amyloid therapies. Brain swelling, or edema, was reported as a side effect in 119 patients across the reviewed trials, and a small but measurable increase in cerebral microhemorrhages was also documented. Co-author Edo Richard, a neurologist from Radboud University Medical Center in the Netherlands, stated that the results refute the foundational assumption driving decades of research. „Our results refute the assumption that the removal of amyloids would benefit patients.” — Edo Richard via stern.de Richard called for Alzheimer's research to turn toward other disease mechanisms. The review's authors also warned against overvaluing individual positive studies when a broader body of negative results exists, and they noted that the mere delay of disease progression by weeks or months — while potentially meaningful to individual patients and families — was not decisive for their primary assessment of clinical relevance.

Scientific community divided over methodology and what comes next The Cochrane review has not gone unchallenged within the scientific community. Critics have pointed to the fact that the authors grouped together very different active ingredients, including drugs such as bapineuzumab and gantenerumab that manufacturers had already abandoned years earlier due to lack of efficacy. Some researchers argue that data from failed compounds should not be combined with results from newer, more targeted therapies such as lecanemab and donanemab. The authors defended their methodology at an online press conference, stating they had conducted additional analyses to check for possible biases, and that the overall picture did not change significantly as a result. Jordi Pérez-Tur, a researcher at the Institut de Biomedicina de València and the Center for Networked Biomedical Research on Neurodegenerative Diseases, noted that authorization processes for the first drugs in this class had already been accompanied by academic controversy, with members of both the U.S. Food and Drug Administration and the European Medicines Agency advisory committees questioning the scant clinical effect at the time of approval.

The so-called amyloid hypothesis has guided Alzheimer's research for decades, based on the premise that removing beta-amyloid protein plaques from the brain would slow neurodegeneration. Major pharmaceutical companies developed a generation of monoclonal antibodies under this framework, including aducanumab, which the U.S. FDA approved in 2021 despite opposition from part of its advisory committee. Lecanemab and donanemab followed, receiving approvals in several countries amid divergent decisions by health authorities on reimbursement. Previous clinical trials had reported reductions in cognitive decline of around 25 to 35 percent, though many experts cautioned that statistically significant results did not necessarily translate into clinically meaningful improvements for patients. Alzheimer's disease affects approximately 40 million people worldwide, according to the World Health Organization, with roughly 800,000 cases recorded in Spain alone.